Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Gains Anti-Inflammatory Compound Development Rights Through Incyte Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Under the agreement for CCR2 antagonists, Incyte will maintain rights to multiple sclerosis and a second undisclosed indication.

You may also be interested in...



Phase II Diabetes Data Heighten Incyte’s Partnership Appeal

Novel compound that acts on cortisol gives DPP-4 inhibitors a run for their money.

Phase II Diabetes Data Heighten Incyte’s Partnership Appeal

Novel compound that acts on cortisol gives DPP-4 inhibitors a run for their money.

Multiple Internal Champions Can Propel Complex Licensing Deals, Pfizer Exec Says

Incyte deal is a model for negotiations involving multiple therapeutic areas, Pfizer exec tells licensing meeting.

Topics

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel